Topic: Vectibix
Amgen Inc. (AMGN). . Executives. . Robert A. Bradway - President, Chief Operating Officer and Director. . Analysts. . Geoffrey C. Meacham - JP...
Posted on 06/24/11 at 11:00am by Benzinga Staff . Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use of...
Posted on 03/30/11 at 4:06pm by Benzinga Staff . Amgen (Nasdaq: AMGN ) announced today that it has submitted a request to the European Medicines...
Amgen (AMGN) reported fourth quarter earnings per share of $1.15, 9 cents above the Zacks Consensus Estimate of $1.06 and 11.7% above year-ago...
0 HP shakes up board, plans another Hurd probe . Hewlett-Packard appointed five new members to its board on Thursday, including Meg Whitman, the...
Vectibix is a cancer drug which is used to treat types of colon or rectal cancers that have become serious in their spread through parts of the body. Vectibix is often used when other chemotherapy agents have been used and have failed ...
Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy. Amgen is exploring numerous biologic pathways ...
THOUSAND OAKS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal ...
Biotech company Amgen (AMGN) recently reported disappointing results on its oncology drug, Vectibix, which was being studied for the first-line treatment of head and neck cancer. Vectibix' failure in the head and neck cancer trial is a disappointment for Amgen. Although Vectibix ...
The colon cancer Vectibix did not improve survival in head-and-neck cancer, maker Amgen announced this morning. Most analysts are focusing more on the company's bone drug, Prolia, than on Vectibix, which generated just $72 million in sales in the most recent ...
Video Gallery
-
Amgen - Mecanismo de Ação Vectibix
Cliente: Amgen Produto: Nacionalização Agência: D'Lucca Duração: 6'14 ...2011-10-04 -
Surviving Colon Cancer - Stage 4 Survivors
David Dean is a stage 4 colon cancer survivor who ...2011-11-11 -
Dr Tony Talebi discusses the treatment ...
Dr Tony Talebi discusses the treatment of stage IV metastatic ...2011-11-17
